MARKET

GALT

GALT

Galectin Therapeutics Inc
NASDAQ
4.160
+0.080
+1.96%
After Hours: 4.160 0 0.00% 19:55 12/31 EST
OPEN
4.090
PREV CLOSE
4.080
HIGH
4.200
LOW
4.015
VOLUME
325.58K
TURNOVER
--
52 WEEK HIGH
7.13
52 WEEK LOW
0.9400
MARKET CAP
268.21M
P/E (TTM)
-7.0353
1D
5D
1M
3M
1Y
5Y
1D
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm
Barchart · 12/29/2025 20:54
Weekly Report: what happened at GALT last week (1222-1226)?
Weekly Report · 12/29/2025 09:10
Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains
Seeking Alpha · 12/24/2025 12:45
Insider Makes Bold Move on Galectin Therapeutics Stock
TipRanks · 12/24/2025 02:01
Galectin Therapeutics Director Kary Eldred Reports Acquisition of Common Shares
Reuters · 12/23/2025 18:18
Galectin Therapeutics Director Kevin D. Freeman Reports Acquisition of Common Shares
Reuters · 12/23/2025 16:29
Director Kary Eldred Acquires Common Shares of Galectin Therapeutics Inc
Reuters · 12/23/2025 16:29
Weekly Report: what happened at GALT last week (1215-1219)?
Weekly Report · 12/22/2025 09:10
More
About GALT
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.

Webull offers Galectin Therapeutics Inc stock information, including NASDAQ: GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.